The RSM has an extensive digital learning and online e-resources platform. As a member you'll enjoy free access to a wealth of online resources, including 5,000 subscription and open access e-journals, 2,000 e-books and 5 key medical databases, to support your clinical decision-making and research.
- Date and time Fri 2 Jul 2021 from 8:30am to 4:30pm
- Location Royal Society of Medicine
- Organised by Urology
This event has been cancelled. Apologies for any inconvenience this may have caused. Delegates will be emailed shortly.
This meeting will explore the evidence for intervention with medical hormonal therapy in adolescents with gender dysphoria and the effects of this approach.
The use of gonadotropin-releasing hormone (GnRH) agonists (more commonly known as hormone or puberty blockers) in transgender adolescents is a contentious topic in regards to the ethics of treating children, evidence-based medicine and long term effects.
The early use of blockers has been suggested as reversible but as treatment of this group increases, issues and challenges in regards to fertility preservation and the effects of future gender reassignment surgery, cognitive and bone health have been highlighted.
This area is very controversial, in society and medical practice, with a judicial review ongoing together with a NICE Review of Evidence. In addition, there is a High Court Case challenging the Gillick Competency in adolescents.
This meeting will provide a balanced and informed debate into the current practice affecting medical practitioners from urology, gynaecology, endocrinology and psychiatry.
- The evidence for medical intervention in adolescent dysphoria
- Highlight and understand the controversies in this area
- The roles of all gender identity specialists in adolescent dysphoria
- Provide a template for future research and management in this challenging area
*Please note we will need to check all GMC numbers of attendees to this meeting. Ensure you bring this with you, attendance may be denied otherwise.